These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 32869173)

  • 1. Tolvaptan treatment in hyponatremia due to the syndrome of inappropriate secretion of antidiuretic hormone (SIADH): effects on survival in patients with cancer.
    Bilgetekin I; Erturk I; Basal FB; Karacin C; Karadurmus N; Oksuzoglu B; Demirci U
    Int Urol Nephrol; 2021 Feb; 53(2):301-307. PubMed ID: 32869173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapidity of Correction of Hyponatremia Due to Syndrome of Inappropriate Secretion of Antidiuretic Hormone Following Tolvaptan.
    Morris JH; Bohm NM; Nemecek BD; Crawford R; Kelley D; Bhasin B; Nietert PJ; Velez JCQ
    Am J Kidney Dis; 2018 Jun; 71(6):772-782. PubMed ID: 29478867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tolvaptan use in cancer patients with hyponatremia due to the syndrome of inappropriate antidiuretic hormone: a post hoc analysis of the SALT-1 and SALT-2 trials.
    Gralla RJ; Ahmad F; Blais JD; Chiodo J; Zhou W; Glaser LA; Czerwiec FS
    Cancer Med; 2017 Apr; 6(4):723-729. PubMed ID: 28251822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A retrospective study on tolvaptan prescription in clinical practice in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH) using the Japanese claims database.
    Hagiwara D; Matsukawa M; Tasaki J; Nakamura Y; Arima H
    Endocr J; 2023 Dec; 70(12):1195-1205. PubMed ID: 37914256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, double blinded, placebo-controlled trial to evaluate the efficacy and safety of tolvaptan in Chinese patients with hyponatremia caused by SIADH.
    Chen S; Zhao JJ; Tong NW; Guo XH; Qiu MC; Yang GY; Liu ZM; Ma JH; Zhang ZW; Gu F
    J Clin Pharmacol; 2014 Dec; 54(12):1362-7. PubMed ID: 24906029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SIADH-related hyponatremia in hospital day care units: clinical experience and management with tolvaptan.
    De Las Peñas R; Ponce S; Henao F; Camps Herrero C; Carcereny E; Escobar Álvarez Y; Rodríguez CA; Virizuela JA; López López R
    Support Care Cancer; 2016 Jan; 24(1):499-507. PubMed ID: 26431960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using Tolvaptan to Treat Hyponatremia: Results from a Post-authorization Pharmacovigilance Study.
    Estilo A; McCormick L; Rahman M
    Adv Ther; 2021 Dec; 38(12):5721-5736. PubMed ID: 34693505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolvaptan for Treatment of Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) in a Child with Corpus Callosum Agenesis.
    Meena AK; Nanda PM; Sharma R; Chakrabarty B; Gulati S
    Indian J Pediatr; 2024 Feb; 91(2):188-190. PubMed ID: 36757652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of tolvaptan on hyponatremia in a dog with syndrome of inappropriate secretion of antidiuretic hormone.
    Yamamoto H; Kimura K; Horikirizono H; Tamura Y; Kambayashi S; Baba K; Okuda M; Mizuno T; Igase M
    J Vet Med Sci; 2023 Oct; 85(10):1047-1051. PubMed ID: 37587049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case report: Secondary failure to tolvaptan in a patient with SCLC and paraneoplastic SIADH.
    Menzi S; Jaramillo SD; Pfister S; Schefer H; Jehle AW
    Front Endocrinol (Lausanne); 2024; 15():1382066. PubMed ID: 38803472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of Tolvaptan in Korean Patients with Hyponatremia Caused by the Syndrome of Inappropriate Antidiuretic Hormone.
    Han SW; Yi JH; Kang KP; Kim HY; Kim SW; Choi HY; Ha SK; Kim GH; Kim YW; Jeong KH; Shin SK; Kim HJ
    J Korean Med Sci; 2018 Apr; 33(15):e112. PubMed ID: 29629516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficiency of Single Dose of Tolvaptan Treatment During the Triphasic Episode After Surgery for Craniopharyngioma.
    Gürbüz F; Taştan M; Turan İ; Yüksel B
    J Clin Res Pediatr Endocrinol; 2019 May; 11(2):202-206. PubMed ID: 30257818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Case report: Twice-daily tolvaptan dosing regimen in a challenging case of hyponatremia due to SIAD.
    Arecco A; Demontis D; Della Sala L; Musso N; Gay S; Boschetti M; Ferone D; Gatto F
    Front Endocrinol (Lausanne); 2023; 14():1309657. PubMed ID: 38288467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An economic analysis of tolvaptan compared with fluid restriction among hospitalized patients with hyponatremia.
    Ramamohan V; Mladsi D; Ronquest N; Kamat S; Boklage S
    Hosp Pract (1995); 2017 Aug; 45(3):111-117. PubMed ID: 28449624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolvaptan in the Management of Acute Euvolemic Hyponatremia After Transsphenoidal Surgery: A Retrospective Single-Center Analysis.
    Indirli R; Ferreira de Carvalho J; Cremaschi A; Mantovani B; Sala E; Serban AL; Locatelli M; Bertani G; Carosi G; Fiore G; Tariciotti L; Arosio M; Mantovani G; Ferrante E
    Front Endocrinol (Lausanne); 2021; 12():689887. PubMed ID: 34108941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of costs associated with tolvaptan-mediated hospital length of stay reduction among US patients with the syndrome of inappropriate antidiuretic hormone secretion, based on SALT-1 and SALT-2 trials.
    Dasta JF; Chiong JR; Christian R; Lin J
    Hosp Pract (1995); 2012 Feb; 40(1):7-14. PubMed ID: 22406878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of tolvaptan for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion in Sweden.
    Jamookeeah C; Robinson P; O'Reilly K; Lundberg J; Gisby M; Ländin M; Skov J; Trueman D
    BMC Endocr Disord; 2016 May; 16(1):22. PubMed ID: 27184496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Open-label, multicenter, dose-titration study to determine the efficacy and safety of tolvaptan in Japanese patients with hyponatremia secondary to syndrome of inappropriate secretion of antidiuretic hormone.
    Arima H; Goto K; Motozawa T; Mouri M; Watanabe R; Hirano T; Ishikawa SE
    Endocr J; 2021 Jan; 68(1):17-29. PubMed ID: 32863282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uric acid levels with tolvaptan treatment for syndrome of inappropriate antidiuretic hormone secretion.
    Nagamine T
    Endocrine; 2024 Mar; 83(3):826-827. PubMed ID: 37982946
    [No Abstract]   [Full Text] [Related]  

  • 20. Prompt efficacy of tolvaptan in treating hyponatremia of syndrome of inappropriate secretion of antidiuretic hormone (SIADH) closely associated with rupture of a gastric artery aneurysm.
    Yamashita T; Yoshida M; Yamada H; Asano T; Aoki A; Ikoma A; Kusaka I; Kakei M; Ishikawa SE
    Intern Med; 2014; 53(8):845-9. PubMed ID: 24739604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.